Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mesothelioma, Malignant 2Melanoma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Somatostatinoma 1Solitary Fibrous Tumor, Pleural 1Primary Myelofibrosis 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Metastatic Non-hematologic Malignancies 1Meningioma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Everolimus 3Temozolomide 2Leucovorin 2Fluorouracil 2Bevacizumab 2vatalanib 1temsirolimus 1regorafenib 1pentetreotide 1pazopanib 1folfirinox 1Vinorelbine 1Thalidomide 1Sirolimus 1Oxaliplatin 1Octreotide 1Irinotecan 1High-Energy Shock Waves 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cytokines 1Capecitabine 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Islet Cell × vatalanib × Clear all
NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
96 enrolled
DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡